In a significant move, Fortis Healthcare has successfully acquired the ‘Fortis’ trademark through a public auction, placing a winning bid of ₹200 crore. The acquisition follows a directive issued by the Delhi High Court, which had ordered the sale of the trademark and its associated marks in compliance with a Supreme Court ruling from September 22, 2022.
The trademarks, previously owned by entities controlled by the company's former promoters, were attached by the court to settle a decree in favor of Daiichi Sankyo Company Limited. This development stems from a long-standing legal dispute between the Japanese pharmaceutical giant and the former promoters of Fortis Healthcare.
Following the court’s directive on October 29, 2024, a public auction was conducted, where Fortis Healthcare emerged as the highest bidder, securing the rights to the ‘Fortis’ brand. The company disclosed this acquisition in a regulatory filing, emphasizing the strategic importance of reclaiming its brand identity.
The Delhi High Court, in a judgment dated March 25, 2025, officially confirmed the transfer of the Fortis Marks and all related rights and obligations to Fortis Healthcare. This ruling cements the company’s ownership of its trademark, ensuring brand continuity and eliminating any uncertainties surrounding its intellectual property.
This landmark decision reinforces Fortis Healthcare’s position in the healthcare sector, allowing it to operate under its well-established brand name without any external claims. The acquisition marks a crucial step in the company’s journey, securing its legacy and future operations under a unified brand identity.